Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytek Biosciences, Inc. (Nasdaq: CTKB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer on the Nasdaq Global Select Market. These documents help investors and analysts understand Cytek’s financial condition, operating results and governance as a cell analysis solutions company focused on Full Spectrum Profiling™ (FSP®) flow cytometry instruments, reagents and services.
Cytek submits Form 10-Q quarterly reports and Form 10-K annual reports, which include details on revenue from products, services and reagents, gross margins, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as information on cash and marketable securities. These filings also discuss risk factors, market conditions and other elements relevant to its analytical laboratory instrument manufacturing business.
The company also files Form 8-K current reports to disclose material events. Recent 8-K filings have covered quarterly financial results under Item 2.02 (Results of Operations and Financial Condition) and outcomes of the annual meeting of stockholders under Item 5.07, including votes on director elections, executive compensation and ratification of the independent registered public accounting firm.
In addition, investors can review exhibits attached to these filings, such as press releases furnished as Exhibit 99.1, which provide narrative context for the numbers reported. Over time, the filings record Cytek’s progress in areas such as recurring revenue growth from services and reagents, expansion of its installed instrument base and capital allocation decisions.
On Stock Titan, Cytek’s SEC filings are updated in near real time from the EDGAR system. AI-powered summaries highlight key points from lengthy 10-K and 10-Q reports, and help users quickly identify information on revenue composition, operating trends and risk disclosures. The page also makes it easier to locate Form 4 and other insider-related filings when available, supporting research into trading activity and governance practices at CTKB.
Cytek Biosciences (CTKB) held its 2025 Annual Meeting on June 18, with 81.4% of outstanding shares represented. Key voting results include:
- Director Elections: Richard Chin, MD was elected with strong support (81.7M votes for), while Deborah Neff faced significant opposition with only 33.8M votes for and 48.1M votes withheld
- Executive Compensation: Shareholders approved 2024 executive compensation in a non-binding advisory vote, with 76.3M votes in favor versus 5.6M against
- Auditor Ratification: Deloitte & Touche LLP was confirmed as independent auditor for FY2025, receiving 95.8M votes in favor (92.3% approval)
The mixed voting results, particularly regarding Deborah Neff's election, suggest some shareholder concerns about board composition. However, strong support for executive compensation and auditor selection indicates general satisfaction with company management and governance.
Cytek Biosciences (CTKB) filed a Form 4 disclosing new equity awards to independent director Richard Chin on 18 June 2025. The filing shows 73,289 Restricted Stock Units (RSUs) and 39,062 non-qualified stock options granted at an exercise price of $3.07 per share. No shares were sold.
The RSUs convert 1-for-1 into common stock once vested. Vesting spans three years, with 2/36 of the award vesting on 18 Aug 2025 and 3/36 vesting on each scheduled quarterly date thereafter until fully vested in August 2028. The stock options vest monthly at a rate of 1/36 over the same three-year period and expire on 17 Jun 2035, potentially adding another 39,062 shares to the float if exercised.
Following the grant, Chin holds all 112,351 derivative securities directly. The transaction represents routine director compensation and introduces a modest dilutive overhang but aligns the director’s incentives with shareholder value.
Form 3 overview: Cytek Biosciences, Inc. (CTKB) filed an Initial Statement of Beneficial Ownership for newly appointed director Richard Chin covering the reportable event date of 06/18/2025. The filing is required under Section 16(a) to disclose any equity interest held by insiders at the moment they become subject to reporting obligations.
Key disclosure: Table I and Table II are blank and the “Explanation of Responses” section states “No securities are beneficially owned.” Accordingly, Dr. Chin reports zero direct or indirect ownership of Cytek common shares or derivative securities as of the event date.
Governance context: Because Form 3 establishes the baseline from which future changes will be measured, investors can expect subsequent Form 4 filings if and when the director acquires stock or options. The document was signed by attorney-in-fact Valerie Barnett on 06/20/2025.
Cytek Biosciences, Inc. (CTKB) – Form 4 insider filing, 20 Jun 2025
Director Deborah J. Neff reported two equity awards granted on 18 Jun 2025 as part of routine board compensation.
- Restricted Stock Units (RSUs): 43,973 units, each convertible into one share of common stock. Vesting: 100 % vests on the earlier of 18 Jun 2026 or the company’s 2026 annual shareholder meeting (if held in June 2026). Until vesting, the units remain contingent and non-transferable.
- Non-qualified Stock Options: 23,809 options with an exercise price of $3.07 per share. Vesting mirrors the RSUs—100 % on the earlier of 18 Jun 2026 or the 2026 annual meeting—and the options expire on 18 Jun 2035, giving a 10-year life after vesting.
Both awards are recorded as “A” (acquired) transactions, increasing the director’s derivative holdings to 43,973 RSUs and 23,809 options. No common-stock sales or purchases were disclosed, and no non-derivative ownership changes were reported.
Because the combined 67,782 potentially issuable shares represent a very small fraction of Cytek’s total shares outstanding, the filing is primarily informational and typical for board-level equity incentives. The grant reinforces alignment between the director and shareholders but does not, on its own, alter the company’s capital structure or financial outlook.
Cytek Biosciences, Inc. (CTKB) – Form 4 filing dated 06/20/2025
The filing discloses new equity awards granted to director Jack Ball on 06/18/2025. Two separate instruments were reported:
- Restricted Stock Units (RSUs): 43,973 units, each convertible into one common share. 100 % of the award vests on the earlier of 18 Jun 2026 or the company’s 2026 annual meeting (if held in June 2026). Upon vesting, Ball will receive an equivalent number of common shares.
- Non-qualified Stock Option: Right to purchase 23,809 common shares at an exercise price of $3.07 per share. The option follows the same vesting schedule as the RSUs and carries an expiration date of 18 Jun 2035.
Following these grants, Ball’s directly held derivative positions now include the 43,973 RSUs and 23,809 options; no indirect ownership was reported. The filing does not indicate any sale or disposition of existing shares, and no Rule 10b5-1 trading plan box was checked.
The awards represent routine director compensation and do not provide quantitative information on Cytek’s overall share count, dilution impact, or financial performance. No earnings data, cash payments, or other material corporate actions accompany the disclosure.
Form 4 snapshot: On 18 June 2025 Cytek Biosciences (CTKB) reported that director Michael Holder received two equity awards – 43,973 Restricted Stock Units (RSUs) and 23,809 non-qualified stock options – both coded “A” for acquisition.
Key terms:
- RSUs: One RSU converts into one common share; no cash paid.
- Options: Exercise price set at $3.07, indicating the share price on grant date.
- Vesting for both awards: 100% on the earlier of 18 June 2026 or the 2026 annual meeting (if held in June 2026).
Post-transaction ownership: Holder now directly holds 43,973 RSUs and 23,809 options, representing a potential 67,782 new shares if fully vested and exercised. No sales, dispositions or open-market purchases were disclosed.
Investor takeaway: The filing reflects routine board compensation, aligns the director’s interests with shareholders for at least the next year and introduces only minor potential dilution relative to the company’s total shares outstanding. No information affecting earnings, cash flow or strategy was provided.